Thirty Days

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Retrieved on: 
Tuesday, October 3, 2023
Travel, Hematopoietic stem cell transplantation, AUC, AL amyloidosis, Thirty Days, MRD, Hadassah Medical Center, AL, Patient, IMS, Amyloidosis, LOS, Daratumumab, BCMA, Pharmaceutical industry, Hospital, Immunotherapy

One new patient and additional follow-up data from an additional 8 patients (9 total) are included in this update.

Key Points: 
  • One new patient and additional follow-up data from an additional 8 patients (9 total) are included in this update.
  • “NXC-201’s 100% response rate in relapsed/refractory AL amyloidosis patients, including t(11;14) and cardiac involved, indicates a potential broad mechanism of action.
  • Median follow-up was 7.3 months (range: 2.5 – 16.5 months) as of the September 20, 2023 data cutoff.
  • Data highlights:
    Best responder had a duration of response of 19.2 months as of the data cutoff of September 20, 2023, with response ongoing
    For the 7 relapsed/refractory AL Amyloidosis patients with cardiac involvement:
    4 patients with t(11;14) relapsed/refractory AL Amyloidosis:
    The 20th IMS AL Amyloidosis presentation can be accessed on the ImmixBio corporate website at this link: https://immixbio.com/pipeline/#publications
    20th International Myeloma Society Annual Meeting, Athens, Greece